Application of APOA5 inhibitor in prevention and treatment of PD-L1 high-expression liver diseases and screening of drugs for regulating liver immune inflammatory microenvironment homeostasis
By developing APOA5 inhibitors to regulate the expression and activity of APOA5, the treatment problem of acute liver injury in sepsis was solved, and the effect of reducing hepatic cell apoptosis and reducing inflammatory factors was achieved, providing a new treatment approach for liver injury in sepsis.
Patent Information
- Application Number
- CN202510528359.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-04-25
- Publication Date
- 2025-08-15
AI Technical Summary
In the prior art, sepsis-related acute liver injury (SALI) in early stages of sepsis lacks effective treatment methods, and the application of anti-PD-L1 therapy in sepsis is challenging. Direct regulation of PD-L1 expression is complex and it is difficult to effectively alleviate liver injury caused by sepsis.
By developing APOA5 inhibitors, the expression, secretion and activity of APOA5 are reduced, and the expression of PD-L1 is reduced, especially in macrophages. APOA5 is used as an alternative pathway for PD-L1 inhibitors, and small-molecular compounds such as metformin or gene editing techniques such as CRISPR-Cas9 knock out the APOA5 gene to regulate the liver immune microenvironment.
Effectively reduce hepatocyte apoptosis, reduce the level of macrophage inflammatory factors, prolong the survival time of mice with acute liver injury in sepsis, and reduce liver damage, providing a potential therapeutic target for acute liver injury in sepsis, and replacing direct anti-PD-L1 treatment methods.